These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9871603)

  • 1. Nonpeptide glycoprotein IIb/IIIa inhibitors: substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists.
    Liverton NJ; Armstrong DJ; Claremon DA; Remy DC; Baldwin JJ; Lynch RJ; Zhang G; Gould RJ
    Bioorg Med Chem Lett; 1998 Mar; 8(5):483-6. PubMed ID: 9871603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes.
    Mehrotra MM; Heath JA; Rose JW; Smyth MS; Seroogy J; Volkots DL; Ruhter G; Schotten T; Alaimo L; Park G; Pandey A; Scarborough RM
    Bioorg Med Chem Lett; 2002 Apr; 12(7):1103-7. PubMed ID: 11909727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes.
    Smyth MS; Rose J; Mehrotra MM; Heath J; Ruhter G; Schotten T; Seroogy J; Volkots D; Pandey A; Scarborough RM
    Bioorg Med Chem Lett; 2001 May; 11(10):1289-92. PubMed ID: 11392539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes.
    Pandey A; Seroogy J; Volkots D; Smyth MS; Rose J; Mehrotra MM; Heath J; Ruhter G; Schotten T; Scarborough RM
    Bioorg Med Chem Lett; 2001 May; 11(10):1293-6. PubMed ID: 11392540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet glycoprotein IIb/IIIa receptor antagonists derived from isoxazolidines.
    Confalone PN; Jin F; Mousa SA
    Bioorg Med Chem Lett; 1999 Jan; 9(1):55-8. PubMed ID: 9990456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological evaluation and molecular docking studies of 2-piperazin-1-yl-quinazolines as platelet aggregation inhibitors and ligands of integrin αIIbβ3.
    Krysko AA; Kornylov AY; Polishchuk PG; Samoylenko GV; Krysko OL; Kabanova TA; Kravtsov VCh; Kabanov VM; Wicher B; Andronati SA
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1839-43. PubMed ID: 26912112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications.
    Andronati SA; Karaseva TL; Krysko AA
    Curr Med Chem; 2004 May; 11(9):1183-211. PubMed ID: 15134514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
    Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
    J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and pharmacology of modified amidine isoxazoline glycoprotein IIb/IIIa receptor antagonists.
    Sielecki TM; Liu J; Mousa SA; Racanelli AL; Hausner EA; Wexler RR; Olson RE
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2201-4. PubMed ID: 11514170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.
    Sugihara H; Fukushi H; Miyawaki T; Imai Y; Terashita Z; Kawamura M; Fujisawa Y; Kita S
    J Med Chem; 1998 Feb; 41(4):489-502. PubMed ID: 9484499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the research of GPIIb/IIIa antagonists.
    Xie Z; Cao C; Feng S; Huang J; Li Z
    Future Med Chem; 2015; 7(9):1149-71. PubMed ID: 26132524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of a series of indole glycoprotein IIb/IIIa inhibitors.
    Grumel V; Mérour JY; Lesur B; Giboulot T; Frydman A; Guillaumet G
    Eur J Med Chem; 2002 Jan; 37(1):45-62. PubMed ID: 11841874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
    J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and properties of peptidomimetics--inhibitors of platelet aggregation.
    Andronati SA; Krysko AA; Kabanov VM; Karaseva TL; Kabanova TA
    Acta Pol Pharm; 2000 Nov; 57 Suppl():15-21. PubMed ID: 11293251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel antagonists of glycoprotein IIb/IIIa-mediated platelet aggregation through virtual screening.
    Wang Y; Zhao Y; Sun R; Kong W; Wang B; Yang G; Li Y
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1249-53. PubMed ID: 25677660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
    Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
    Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antiplatelet effects of an isoxazole series of glycoprotein IIb/IIIa antagonists.
    Xue CB; Roderick J; Mousa S; Olson RE; DeGrado WF
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3499-504. PubMed ID: 9934460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-platelet approach targeting the fibrinogen ligand of the GPIIB/IIIa receptor.
    Tsikaris V
    J Pept Sci; 2004 Oct; 10(10):589-602. PubMed ID: 15526708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
    Li YF; Spencer FA; Becker RC
    Am Heart J; 2002 Apr; 143(4):725-32. PubMed ID: 11923812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.